These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 16637077)

  • 1. Biochemical progression rates in the screen arm compared to the control arm of the Rotterdam Section of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
    Roemeling S; Roobol MJ; Gosselaar C; Schröder FH
    Prostate; 2006 Jul; 66(10):1076-81. PubMed ID: 16637077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam.
    Roobol MJ; Grenabo A; Schröder FH; Hugosson J
    J Natl Cancer Inst; 2007 Sep; 99(17):1296-303. PubMed ID: 17728218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extent of prostate-specific antigen contamination in the Spanish section of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
    Luján M; Páez A; Pascual C; Angulo J; Miravalles E; Berenguer A
    Eur Urol; 2006 Dec; 50(6):1234-40; discussion 1239-40. PubMed ID: 16704893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up.
    Zhu X; van Leeuwen PJ; Bul M; Otto SJ; de Koning HJ; Bangma CH; Schröder FH; Roobol MJ
    Eur Urol; 2011 Aug; 60(2):330-6. PubMed ID: 21601352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumour features in the control and screening arm of a randomized trial of prostate cancer.
    Postma R; van Leenders AG; Roobol MJ; Schröder FH; van der Kwast TH
    Eur Urol; 2006 Jul; 50(1):70-5. PubMed ID: 16434136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of screen detected and clinically diagnosed prostate cancer in the European randomized study of screening for prostate cancer, section rotterdam.
    van der Cruijsen-Koeter IW; Vis AN; Roobol MJ; Wildhagen MF; de Koning HJ; van der Kwast TH; Schröder FH
    J Urol; 2005 Jul; 174(1):121-5. PubMed ID: 15947595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC.
    Schröder FH; Bangma CH; Roobol MJ
    Eur Urol; 2008 May; 53(5):901-8. PubMed ID: 18262712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
    Schröder FH
    Can J Urol; 2005 Feb; 12 Suppl 1():2-6; discussion 92-3. PubMed ID: 15780157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management and survival of screen-detected prostate cancer patients who might have been suitable for active surveillance.
    Roemeling S; Roobol MJ; Postma R; Gosselaar C; van der Kwast TH; Bangma CH; Schröder FH
    Eur Urol; 2006 Sep; 50(3):475-82. PubMed ID: 16713065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Results and participation factors to the European Randomized study of Screening for Prostate Cancer (ERSPC) with Prostate Specific Antigen: French departments of Tarn and Hérault].
    Jegu J; Tretarre B; Grosclaude P; Rebillard X; Bataille V; Malavaud B; Iborra F; Salama G; Rischmann P; Villers A
    Prog Urol; 2009 Jul; 19(7):487-98. PubMed ID: 19559380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 4-year prostate specific antigen progression and diagnosis of prostate cancer in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
    Schröder FH; Raaijmakers R; Postma R; van der Kwast TH; Roobol MJ
    J Urol; 2005 Aug; 174(2):489-94; discussion 493-4. PubMed ID: 16006878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival results in patients with screen-detected prostate cancer versus physician-referred patients treated with radical prostatectomy: early results.
    Roehl KA; Eggener SE; Loeb S; Smith ND; Antenor JA; Catalona WJ
    Urol Oncol; 2006; 24(6):465-71. PubMed ID: 17138126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases.
    Freedland SJ; Sun L; Kane CJ; Presti JC; Terris MK; Amling CL; Moul JW; Aronson WJ
    BJU Int; 2008 Sep; 102(8):969-74. PubMed ID: 18691175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening for prostate cancer (PC)--an update on recent findings of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
    Schröder FH
    Urol Oncol; 2008; 26(5):533-41. PubMed ID: 18774469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metastatic disease of screen-detected prostate cancer : characteristics at diagnosis.
    Roemeling S; Kranse R; Vis AN; Gosselaar C; van der Kwast TH; Schröder FH
    Cancer; 2006 Dec; 107(12):2779-85. PubMed ID: 17109445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC)--Section Rotterdam. A comparison of two rounds of screening.
    Postma R; Schröder FH; van Leenders GJ; Hoedemaeker RF; Vis AN; Roobol MJ; van der Kwast TH
    Eur Urol; 2007 Jul; 52(1):89-97. PubMed ID: 17257742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. hK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screen-detected men within the PSA range 4-10 ng/ml.
    Raaijmakers R; de Vries SH; Blijenberg BG; Wildhagen MF; Postma R; Bangma CH; Darte C; Schröder FH
    Eur Urol; 2007 Nov; 52(5):1358-64. PubMed ID: 17499425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial: characteristics, PSA doubling times, and outcome.
    Roemeling S; Roobol MJ; de Vries SH; Wolters T; Gosselaar C; van Leenders GJ; Schröder FH
    Eur Urol; 2007 May; 51(5):1244-50; discussion 1251. PubMed ID: 17161520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor characteristics and prognostic factors in two subsequent screening rounds with four-year interval within prostate cancer screening trial, ERSPC Rotterdam.
    van der Cruijsen-Koeter IW; Roobol MJ; Wildhagen MF; van der Kwast TH; Kirkels WJ; Schröder FH
    Urology; 2006 Sep; 68(3):615-20. PubMed ID: 17010732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit.
    van Leeuwen PJ; Connolly D; Gavin A; Roobol MJ; Black A; Bangma CH; Schröder FH
    Eur J Cancer; 2010 Jan; 46(2):377-83. PubMed ID: 19804966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.